Articles related to STROKE

In the OPTION trial, LAAC demonstrated a 56% reduction in bleeding events compared to oral anticoagulation while maintaining equivalent stroke prevention in post-ablation patients.

“Understanding which people are at increased risk of a first stroke and providing support to preserve heart and brain health can help prevent a first stroke.”

Sanbexin’s sublingual formulation offers a potential paradigm shift in acute ischemic stroke treatment, enabling flexible administration outside traditional hospital settings.

Tenecteplase administered up to 24 hours after stroke onset improved functional outcomes in patients with large-vessel occlusion and salvageable brain tissue who lacked access to immediate thrombectomy.

In a Chinese study, tenecteplase administered 4.5 to 24 hours after stroke onset resulted in less disability at 90 days compared to standard treatment, though it carried a higher risk of symptomatic intracranial hemorrhage.

In a randomized trial of 1,412 patients with acute ischemic stroke, reteplase was more likely to result in excellent functional outcomes at 90 days compared to alteplase.